On March 20, 2019, Kishimoto, Satoshi; Nakashimada, Yuichi; Yokota, Riri; Hatanaka, Takaaki; Adachi, Motoyasu; Ito, Yuji published an article.Safety of Bis(2,5-dioxopyrrolidin-1-yl) glutarate The title of the article was Site-Specific Chemical Conjugation of Antibodies by Using Affinity Peptide for the Development of Therapeutic Antibody Format. And the article contained the following:
Artificially modified IgG mols. are increasingly utilized in industrial and clin. applications. In the present study, the method of chem. conjugation by affinity peptide (CCAP) for site-specific chem. modification has been developed by using a peptide that bound with high affinity to human IgG-Fc. This method enabled a rapid modification of a specific residue (Lys248 on Fc) in a one-step reaction under mild condition to form a stable amide bond between the peptide and Fc. The monovalent peptide-IgG conjugate not only maintained complete antigen binding but also bound to Fc receptors (FcRn, FcγRI, and FcγRIIIa), indicating that it is a suitable conjugate form that can be further developed into highly functional antibody therapeutics. CCAP was applied for the preparation of an antibody-drug conjugate and a bispecific antibody to demonstrate the usefulness of this method. The experimental process involved the reaction of Bis(2,5-dioxopyrrolidin-1-yl) glutarate(cas: 79642-50-5).Safety of Bis(2,5-dioxopyrrolidin-1-yl) glutarate
The Article related to igg fc heavy chain peptide conjugation drug conjugate bispecific, Pharmacology: Effects Of Neoplasm Inhibitors and Cytotoxic Agents and other aspects.Safety of Bis(2,5-dioxopyrrolidin-1-yl) glutarate
Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics